Estadificación clínica como factor pronóstico en cáncer de vejiga músculo-invasor

Resumen

El cáncer de vejiga músculo invasor (CV-MI), requiere de una adecuada estadificación clínica y patológica, ya que eso determina las estrategias terapéuticas y el pronóstico de la enfermedad, caracterizada por una alta morbimortalidad. Este articulo tiene como objetivo realizar una revisión de la literatura sobre la exactitud diagnóstica de las técnicas de imagen disponibles para la estadificación clínica de los pacientes con CV-MI y cómo se debería realizar el seguimiento radiológico en los pacientes llevados a cirugía. Para eso se realizó una búsqueda en la base de datos Pubmed de artículos en inglés y en español, se incluyeron artículos de revisión, metanálisis, guías clínicas, estudios retrospectivos y prospectivos de pronóstico y diagnóstico desde el año 1988 hasta el año 2020.

Abstract

Muscle invasive bladder cancer (CV-MI) requires an adequate clinical and pathological staging, as this determines the therapeutic strategies and prognosis of the disease, characterized by high morbidity and mortality. This article aims to carry out a review of the literature on the diagnostic accuracy of the available imaging techniques for the clinical staging of patients with CV-MI and how the radiological follow up should be made in the patients who underwent surgical management of the disease. For this, a search was carried out in the Pubmed database of articles in English and Spanish; review articles, meta-analyzes, clinical guidelines, retrospective and prospective prognosis and diagnosis studies from 1988 to 2020 were included

Palabras clave

Neoplasias de la vejiga urinaria - estadificación de neoplasias - técnicas de diagnóstico urológico - diagnóstico por imagen

Keywords

urinary bladder neoplasms - neoplasm staging - diagnostic imaging

Responsabilidades Éticas

Durante la realización de este artículo de revisión, no se realizaron experimentos que involucren personas o animales, ni se requirió evaluación por parte de algún comité de ética institucional ni la obtención de consentimiento informado por parte de persona alguna. Tampoco se utilizaron datos provenientes de historias clínicas de pacientes o tomados de centros hospitalarios para la elaboración y redacción del presente artículo.

Publication History

Received: 04 May 2020

Accepted: 15 September 2020

Article published online:
04 February 2021

• Referencias

• 1 Mesa A, Nava E, Fernández Del Valle A, Argüelles B, Menéndez-Del Llano R, Sal de Rellán S. Papel de las técnicas de imagen en el diagnóstico y seguimiento del carcinoma vesical músculo invasivo. Actas Urol Esp 2018; 42 (07) 425-434 DOI: 10.1016/j.acuro.2017.08.001.
• 2 Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J. et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013; 49 (06) 1374-1403 DOI: 10.1016/j.ejca.2012.12.027.
• 3 IARC. Estimated age-standardized incidence and mortality rates (World) in 2018, Africa, Tanzania, United Republic of, males, all ages [Internet] [Consultado 3 Dic 2019]. Disponible en: https://gco.iarc.fr/today/online-analysis-map?v=2018&mode=population&mode_population
• 4 Burger M, Catto JWF, Dalbagni G. et al. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013; 63 (02) 234-241 DOI: 10.1016/j.eururo.2012.07.033.
• 5 Lee CH, Tan CH, Faria SC, Kundra V. Role of Imaging in the Local Staging of Urothelial Carcinoma of the Bladder. AJR Am J Roentgenol 2017; 208 (06) 1193-1205 DOI: 10.2214/AJR.16.17114.
• 6 Prout GR, Marshall VF. The prognosis with untreated bladder tumors. Cancer 1956; 9 (03) 551-558 DOI: 10.1002/1097-0142(195605/06)9:3<551:aid-cncr2820090319>3.0.co;2-2.
• 7 Navarro Medina P, Blanco Diez A, Artiles Hernández JL, Chesa Ponce N. Relación clinico-patólogica en cáncer vesical. Actas Urol Esp 2008; 32 (05) 502-506 DOI: 10.1016/s0210-4806(08)73874-9.
• 8 Rafique M, Javed AA. Role of intravenous urography and transabdominal ultrasonography in the diagnosis of bladder carcinoma. Int Braz J Urol 2004; 30 (03) 185-190 , discussion 191 DOI: 10.1590/s1677-55382004000300002.
• 9 Datta SN, Allen GM, Evans R, Vaughton KC, Lucas MG. Urinary tract ultrasonography in the evaluation of haematuria--a report of over 1,000 cases. Ann R Coll Surg Engl 2002; 84 (03) 203-205
• 10 Nicolau C, Bunesch L, Peri L. et al. Accuracy of contrast-enhanced ultrasound in the detection of bladder cancer. Br J Radiol 2011; 84 (1008): 1091-1099 DOI: 10.1259/bjr/43400531.
• 11 Yousem DM, Gatewood OM, Goldman SM, Marshall FF. Synchronous and metachronous transitional cell carcinoma of the urinary tract: prevalence, incidence, and radiographic detection. Radiology 1988; 167 (03) 613-618 DOI: 10.1148/radiology.167.3.3363119.
• 12 Browne RFJ, Meehan CP, Colville J, Power R, Torreggiani WC. Transitional cell carcinoma of the upper urinary tract: spectrum of imaging findings. Radiographics 2005; 25 (06) 1609-1627 DOI: 10.1148/rg.256045517.
• 13 Raman SP, Fishman EK. Bladder malignancies on CT: the underrated role of CT in diagnosis. AJR Am J Roentgenol 2014; 203 (02) 347-354 DOI: 10.2214/AJR.13.12021.
• 14 Sadow CA, Silverman SG, O'Leary MP, Signorovitch JE. Bladder cancer detection with CT urography in an Academic Medical Center. Radiology 2008; 249 (01) 195-202 DOI: 10.1148/radiol.2491071860.
• 15 Jinzaki M, Tanimoto A, Shinmoto H. et al. Detection of bladder tumors with dynamic contrast-enhanced MDCT. AJR Am J Roentgenol 2007; 188 (04) 913-918 DOI: 10.2214/AJR.06.0511.
• 16 Kim JK, Park SY, Ahn HJ, Kim CS, Cho KS. Bladder cancer: analysis of multi-detector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging. Radiology 2004; 231 (03) 725-731 DOI: 10.1148/radiol.2313021253.
• 17 El-Assmy A, Abou-El-Ghar ME, Mosbah A. et al. Bladder tumour staging: comparison of diffusion- and T2-weighted MR imaging. Eur Radiol 2009; 19 (07) 1575-1581 DOI: 10.1007/s00330-009-1340-7.
• 18 Kobayashi S, Koga F, Yoshida S. et al. Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness. Eur Radiol 2011; 21 (10) 2178-2186 DOI: 10.1007/s00330-011-2174-7.
• 19 Baltaci S, Resorlu B, Yagci C, Turkolmez K, Gogus C, Beduk Y. Computerized tomography for detecting perivesical infiltration and lymph node metastasis in invasive bladder carcinoma. Urol Int 2008; 81 (04) 399-402 DOI: 10.1159/000167836.
• 20 Vargas HA, Akin O, Schöder H. et al. Prospective evaluation of MRI, ¹¹C-acetate PET/CT and contrast-enhanced CT for staging of bladder cancer. Eur J Radiol 2012; 81 (12) 4131-4137 DOI: 10.1016/j.ejrad.2012.06.010.
• 21 Tritschler S, Mosler C, Tilki D, Buchner A, Stief C, Graser A. Interobserver variability limits exact preoperative staging by computed tomography in bladder cancer. Urology 2012; 79 (06) 1317-1321 DOI: 10.1016/j.urology.2012.01.040.
• 22 Tritschler S, Mosler C, Straub J. et al. Staging of muscle-invasive bladder cancer: can computerized tomography help us to decide on local treatment?. World J Urol 2012; 30 (06) 827-831 DOI: 10.1007/s00345-011-0817-6.
• 23 Ng CS. Radiologic diagnosis and staging of renal and bladder cancer. Semin Roentgenol 2006; 41 (02) 121-138 DOI: 10.1053/j.ro.2006.02.005.
• 24 Maurer T, Horn T, Heck M, Gschwend JE, Eiber M, Beer AJ. Current Staging Procedures in Urinary Bladder Cancer. Diagnostics (Basel) 2013; 3 (03) 315-324 DOI: 10.3390/diagnostics3030315.
• 25 Verma S, Rajesh A, Prasad SR. et al. Urinary bladder cancer: role of MR imaging. Radiographics 2012; 32 (02) 371-387 DOI: 10.1148/rg.322115125.
• 26 Vikram R, Sandler CM, Ng CS. Imaging and staging of transitional cell carcinoma: part 1, lower urinary tract. AJR Am J Roentgenol 2009; 192 (06) 1481-1487 DOI: 10.2214/AJR.08.1318.
• 27 Oz II, Altinbas NK, Serifoglu I, Oz EB, Yagci C. The Role of Computerized Tomography in the Assessment of Perivesical Invasion in Bladder Cancer. Pol J Radiol 2016; 81: 281-287 DOI: 10.12659/PJR.896752.
• 28 Blanco Díez A, Ruibal Moldes M, Suárez Pascual G. et al. Estadiaje del cáncer de vejiga infiltrante. Papel de la T.A.C. Arch Esp Urol 2003; 56 (01) 23-29
• 29 Tekes A, Kamel I, Imam K. et al. Dynamic MRI of bladder cancer: evaluation of staging accuracy. AJR Am J Roentgenol 2005; 184 (01) 121-127 DOI: 10.2214/ajr.184.1.01840121.
• 30 Boudreaux Jr KJ, Clark PE, Lowrance WT. et al. Comparison of american joint committee on cancer pathological stage T2a versus T2b urothelial carcinoma: analysis of patient outcomes in organ confined bladder cancer. J Urol 2009; 181 (02) 540-545 , discussion 546 DOI: 10.1016/j.juro.2008.10.038.
• 31 Yu RJ, Stein JP, Cai J, Miranda G, Groshen S, Skinner DG. Superficial (pT2a) and deep (pT2b) muscle invasion in pathological staging of bladder cancer following radical cystectomy. J Urol 2006; 176 (02) 493-498 , discussion 498–499 DOI: 10.1016/j.juro.2006.03.065.
• 32 Liedberg F, Bendahl PO, Davidsson T. et al. Preoperative staging of locally advanced bladder cancer before radical cystectomy using 3 tesla magnetic resonance imaging with a standardized protocol. Scand J Urol 2013; 47 (02) 108-112 DOI: 10.3109/00365599.2012.721394.
• 33 McKibben MJ, Woods ME. Preoperative imaging for staging bladder cancer. Curr Urol Rep 2015; 16 (04) 22 DOI: 10.1007/s11934-015-0496-8.
• 34 Kim B, Semelka RC, Ascher SM, Chalpin DB, Carroll PR, Hricak H. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Radiology 1994; 193 (01) 239-245 DOI: 10.1148/radiology.193.1.8090898.
• 35 Ghafoori M, Shakiba M, Ghiasi A, Asvadi N, Hosseini K, Alavi M. Value of MRI in local staging of bladder cancer. Urol J 2013; 10 (02) 866-872
• 36 Witjes JA, Bruins HM, Cathomas R, Compérat E, Cowan NC, Gakis G, Hernández V, Lorch A, Ribal MJ. et al. Muscle-invasive and Metastatic Bladder Cancer Guidelines 2020 [Internet]. EUA 2020 [Consultado marzo 2020]. Disponible en: uroweb.org/guideline/bladder-cancer-muscle-invasive-and-metastatic/
• 37 Nieuwenhuijzen JA, de Vries RR, van Tinteren H. et al. Follow-up after cystectomy: regularly scheduled, risk adjusted, or symptom guided? Patterns of recurrence, relapse presentation, and survival after cystectomy. Eur J Surg Oncol 2014; 40 (12) 1677-1685 DOI: 10.1016/j.ejso.2013.12.017.
• 38 Paik ML, Scolieri MJ, Brown SL, Spirnak JP, Resnick MI. Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. J Urol 2000; 163 (06) 1693-1696
• 39 Lodde M, Lacombe L, Friede J, Morin F, Saourine A, Fradet Y. Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma. BJU Int 2010; 106 (05) 658-663 DOI: 10.1111/j.1464-410X.2010.09212.x.
• 40 Turker P, Bostrom PJ, Wroclawski ML. et al. Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. BJU Int 2012; 110 (06) 804-811 DOI: 10.1111/j.1464-410X.2012.10939.x.
• 41 Chakraborty D, Mittal BR, Kashyap R. et al. Role of fluorodeoxyglucose positron emission tomography/computed tomography in diagnostic evaluation of carcinoma urinary bladder: comparison with computed tomography. World J Nucl Med 2014; 13 (01) 34-39 DOI: 10.4103/1450-1147.138572.
• 42 Swinnen G, Maes A, Pottel H. et al. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Eur Urol 2010; 57 (04) 641-647 DOI: 10.1016/j.eururo.2009.05.014.
• 43 Stenzl A, Cowan NC, De Santis M. et al. Guidelines on Bladder Cancer Muscle-invasive and Metastatic. Eur Urol 2008
• 44 Stenzl A, Cowan NC, De Santis M. et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009; 55 (04) 815-825 DOI: 10.1016/j.eururo.2009.01.002.
• 45 Bochner BH, Montie JE, Lee CT. Follow-up strategies and management of recurrence in urologic oncology bladder cancer: invasive bladder cancer. Urol Clin North Am 2003; 30 (04) 777-789 DOI: 10.1016/s0094-0143(03)00061-2.
• 46 Soukup V, Babjuk M, Bellmunt J. et al. Follow-up after surgical treatment of bladder cancer: a critical analysis of the literature. Eur Urol 2012; 62 (02) 290-302 DOI: 10.1016/j.eururo.2012.05.008.